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Variability in Coronary Hemodynamics in Response to Ergonovine in
Patients With Normal Coronary Arteries and Atypical Chest Pain
ALAN B. SCHWARTZ, MD, T. A. DONMICHAEL, MD, FACC, ELIAS H. BOTVINICK, MD, FACC,
T. ISHIMORI, MD, FACC, WILLIAM W. PARMLEY, MD, FACC,
KANU CHATTERJEE, MB, FRCP, FACC
San Francisco. California
Because an increase incoronaryvascular resistance in
response to ergonovine maleate has been suggested as a
possible diagnostic aid forva iantangina, changes were
evaluated incoronaryhemodynamics and serial myo-
cardialthallium-20lperfusion scans in 15patients with-
out angina and with normal coronary arteries in re-
sponse to ergonovine (0.05, 0.10 and 0.20 mg
intravenously). For the group,heartrate-blood pressure
productincreased significantly (p< 0.001) without any
change incoronarysinus flow, coronary vascular resis-
tance, myocardial oxygen extraction,arterial-coronary
Administrationof ergonovinemaleatehas been used as a
provocativetest forinducingcoronaryartery spasm in pa-
tients withvariantangina(1,2).The test has been found to
be highlysensitiveand specific byangiographicriteria.
Chestpain,electrocardiographicchangesindicative of myo-
cardialischemia,reversiblesevere focalcoronaryartery
narrowing(1-4) and reductionin coronarysinus flow(5-
9) have beenobservedin patientswith spasm,but not in
patientswithoutspasm.Reversiblethalliumscanperfusion
defects have been shown reflectingreductionof regional
myocardialblood flow(10-12).
Measurementof coronarysinus flow has beenreported
to be asensitivetest for thedetectionof coronaryartery
spasm (5). Inpatientswith spasm,a markeddecreasein
coronarysinus flow and an increase incoronaryvascular
resistance(defined as the ratio of mean arterial pressure to
coronarysinus flow) are seen.However,when spasm is
isolated to the rightcoronaryartery,coronarysinus flow
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sinus oxygen difference and lactate extraction. In 7 of
15 patients,however, coronary vascular resistance in-
creased (mean 39%, range 11 to 75%, probability [p]
< 0.001), andcoronarysinusflowdecreased (14%, p<
0.001), despite an increase in heart rate-blood pressure
p oduct(36%, P< 0.02). Noelectrocardiographic,met-
abolic or thallium-201 scan abnormalities occurred.
Therefore,significant increases in coronary vascular re-
sistance in response to ergonovine may occur in patients
with normalcoronaryarteriesand atypical chest pain.
may not be a sensitrve test for spasmbecausethe right
coronaryartery may drain into thecoronarysinus near the
ostium,or directly into the right atrium(13),andtherefore
may notcontributemeasurablytocoronarysinus flow. Al-
though a largereductionin flow in relation todemandhas
been shown in patients with spasm of the leftcoronary
artery, there are few data on the range ofhemodynamicand
metabolicresponsestoergonovinein patients with normal
coronaryarteries(5-8).
We therefore studied a group of patients with chest pain
atypical for angina who had nodocumentedepisodesof
electrocardiographicchangesfor ischemia during chest pain
and whosecoronaryarteriogramand leftventricularangio-
gram were normal. In these patients wedet rminedthe
variationsin coronarysinus flow,coronaryvascularresis-
tance, oxygenconsumptionand lactatemetabolismin re-
sponse toprovocativetesting withergonovinemaleate.
Methods
Study patients (Table 1). Westudied\5consecutivepatients.
5 men(meanage50.4years, range5\ to56)and10women(mean
age 45 years,range16 to 64),referredto us forevaluationof
atypicalchest pain.All but one patient(Case 10)hadpreviously
undergonecardiaccatheterization(a young girl, age17.did not
havecoronaryarteriography).Elevenof14patient, hadnoluminal
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Table 1. Characteristics of Study Group
Chest
CardiacCatheterization
Age Physical X-ray Exer. Cor. LV CCU Ergo.
Case (yrj /Sex History Examination Film ECG Echo Test Art. Anglo Ergo. Date Test Date
I 33F ACP MVP NL NL ECG NL MVP 2/81 4/81
2 64F ACP, HTN, NL NL NL NL BL NL NL 9/80 4/81
PAT
3 55F IV-CABG , NL NL Nonspec. 30% LAD , NL Neg 8/81 4/81
ACP, pseudo- abnor., graftopen
seizures LAHB
4 39F ACP MVP NL NL NL MVP Neg 2/81 2/81
5 59F ACP, MVP NL NL NL ECG , 2mm NL NL 10/80 3/81
FBD, ST!;TL,
LBP NL
6 44F ACP, multiple NL NL NL 30% LAD , NL 6178 9/80
vase, surg. 30% RCA
7 46M OM, ACP NL NL ?IMI NL NL NL NL 1/81 2/81
8 53F ACP,HTN NL NL LVH . LVH TL. rever. 40%LAD NL 1/81 3/81
IMI isch.
9 46F ACP,HTN NL NL NL ECG , 2 mm NL NL 5/80 7/81
ST! ;T1..
NL
10 17F ACP, PAT, MVP NL NL MVP ECG, NL; MVP, 7/80 7/81
migraine, TL,NL ASD
cyclic 0.5:I )
vomiting
II 56M ACP. HTN NL NL NL NL ECG, NL NL NL 6/81 7/81
12 51M ACP, PVC NL NL Freq. ECG , NL NL 12177 9/81
PVCs neg. isch..
VTwlth
exer.
13 41F ACP MR NL NL NL ECG SI! ; NL NL 5179 6/81
Tl.-re ver,
isch.
14 50M ACP NL Pleural Nonspec. NL NL 7/81 10/81
thick. abnor.
15 49M PUD , ACP NL NL Nonspec. NL NL 7/80 11/81
abnor.
AC P = atypical chest pain.AS O = amalseptal defectBL = borderline: IV-CA BG = onevessel coronaryarterybypassgraft:Cor an = coronaryartenography;
CCU = coronarycareunu:OM = diabetesmelitus.ECG = electrocardiogram: Echo= echocardrograrn:Ergo = ergonovineprovocation:Exer.= exercise:I' = female:
FBD = functional boweldisease: Freq. = frequent:HTN = hypenension.IMI = inferiormyocardial infarction: isch= Ischemia: LAD = leftanteriordescend109 coronary
artery, LAHB = left anterior hermblock,LBP = low backpam. LVAngie.= leftventricularangiogram.LVII =lettventricular hypertrophy: M= male. MVP = mural
valve prolapse.Neg. = neganve,Neg Isch = negativefor Ischemia: NL = normal: Nonspec abnor = nonspecific abnormalny: PAT = paroxsyrnalatnal tachycardia.
PUD = pepnculcerdisease: PVCs = premature vcntncularcomplexes. RCA= rightcoronary artery:rever.= reversible.ST L = ST segment depre..ion:Surg= .urgery.
Thick = thickenmg,TL = thalliumscan:vase = vascular:VT = ventnculartachycardia. - = notdoneor notknown
irregularities of any of the coronary arteries. Three patients had a
single insignificant luminal narrowing (decrease in luminal di-
ameter) in one or two coronary vessels (Case 3, 30% lesion in the
left anterior descending coronary artery; Case 8, 40% lesion in the
left anterior descending coronary artery and Case 6. 30% lesions
in the left anterior descending and right coronary arteries). Patient
10 was included in this group even though she did not undergo
prior coronary arteriography because of the absence of symptoms,
risk factors, age and a normal exercise thallium test.
No patient had a documented myocardial infarction or ischemic
electrocardiographic changes with chest pain. Patient 3. who had
one vessel (left anterior descending artery) bypass graft surgery,
underwent repeat catheterization 4 months after this study. A patent
graft and a 30% left anterior descending coronary artery lesion
were found. An ergonovine test was repeated and was negative by
angiographic and electrocardiographic criteria.
Coronary hemodynamic studies. After informed consent was
ob ained, all patients were brought to the coronary care unit where
a radial artery cannula. coronary sinus thermodilution catheter
(Wilton Webster, Inc., Altadena, California) and peripheral intra-
venous lines were placed. The coronary sinus catheter was placed
in the midcoronary sinus to reduce error due to reflux (14) and its
position verified by injection of small amounts of contrast medium
visualized by fluoroscopy at the start and termination of the study.
The catheter was firmly secured to the skin by suture material at
its point of venous entry. CoronarySinUS flows were determined
by the constant infusion thermodilution technique at 46 rnl/rnin
using a Harvard pump and 5% dextrose in water at room temper-
CORONARY HEMODYNAMICS AFTER ERGONOVINE J AM cou,CARDIOl
19~3.1(3) 797-~03
799
ature (14). Coronary sinus flow (CSF) was computed from the
(
Tb - Ti )formula: CSF= 4.6 x 1.08 x - I ml/min,where
Tb - Tm
Tb, Ti and Tmrepresent,respectively , temperature of the blood,
injectate and mixture.
Arterial and coronary sinus venous blood oxygen saturation
were determined using an OSM2hemoximeter(RadiometerCo. ,
Copenhagen,Denmark). Whencomparingthe use of this hemox-
imeter with the Van Slyke method, the standard error of the es-
timate for oxygen content was found to be 0.65 ml/dl, This mea-
surement was not made in duplicate. The error (mean± st dard
deviation) for repeatedd terminationsof oxygen saturation in the
same sample was-0.7 ± 3.1 %.
Oxygen content was calculated from the formula: oxygen con-
tent= oxygen saturationx hemoglobinx 1.34. Lactate (in mg)
wasdeterminedby an automated enzymatic method([5). No du-
plicatemeasurementswere made. The derived variables were cal-
culated as follows:
Rate-pressure product = RP (mm Hg/min x 103) = heart
rate (HR)x systolic pressure (SBP).
Arterial-coronary sinus oxygen content difference (ACD0 2)
(milliter)= arterial-coronarysinus oxygen content.
Myocardial oxygen consumption = MV02 (ml/min) = CSF
(ml/min)x ACD0 2 x 10-3, where CSF= coronary sinus flow.
Myocardial lactate extraction (% lactate)= (arterial-coronary
sinus lactate)/arteriall ctatex 100.
Coronary vascular resistance (CVR) (nun Hg-minlml)= MAPI
CSF, where MAP = mean arterial pressure and CSF= coronary
sinus blood flow.
Studyprotocol.Cardiac medications were discontinued 12 to
24 hours before the study. Blood pressure , a single channel elec-
trocardiographiclead (V5)and coronary sinus flows were recorded
continuouslyon a multichannel strip chart recorder. Two baseline
determinationswere taken 10 minutes apart, consisting of blood
pressure , heart rate, coronary sinus flow, arterial and venous lac-
tate, and oxygen saturation measurements were made. A 12 lead
electrocardiogramwas recorded . Ergonovine maleate was then
given in three doses:0.05,0.10 and 0.20 mg intravenously, at 6
minute intervals . After each dose, a sufficient flush ensured admin-
istration of the full amount. A 12 leadelectrocardiogramwas
recorded every 2 minutes during the study, and patients were asked
for symptoms after the completion of eachelectrocardiogram.If
electrocardiographicchanges were noted, defined as more than I
mm ST deviation from baseline, no larger dose of ergonovine was
given . All patients in this study , however , received the full three
doses ofergonovine.Three minutes after the 0.2 mg dose of
ergonovine, repeat hemodynamic , metabolic and coronary sinus
flow measurements were made. Thallium-201 was injected, and
imaging was performed 5 to 10 minutes later at the bedside with
a portable camera in the anterior , left anterior oblique (30°, 45°
and 60°) and lateral projection views. If defects were detected,
redistribution images were obtained . The anterior image was ac-
quired to 300,000 counts and subsequent images acquired to iso-
time. All images werecomputer-processed according to our stan-
dard method (16).
Sublingual and parenteral nitroglycerin were available if needed.
The test was performed in the coronary care unit with a physician
in attendance at all times. Nocomplications occurred .
Statisticalanalysis.The mean± standard deviation was de-
termined for all data during control and peakergonovinetesting.
Statistical significance was determined by using the pairedt test
to compare data from baseline periods with peak values. A prob-
ability (p) value of less than 0.05 was considered statistically
significant. A nonpairedt test was used to compare the group of
patients whosecoronaryvascular resistance increased (Group A)
with theremainingpatients (Group B).
Two baseline measurements were made 10 minutes apart before
ergonovine stimulation . These measurements were averaged when
less than a 10% difference was observed; otherwise , the second
measurement was used as baseline.
Results
Of the IS patientswho receivedergonovine, II (73%)
developedchestpain. Nopatienthadmyocardialperfusion
defectsduring thallium-201scintigraphyor electrocardio-
graphicchangesduringergonovineprovocationindicative
ofmyocardialischemia.
Hemodynamic and metabolic data (Tables 2 and 3).
Repeatedbaselinemeasurementsofsystemicandcoronary
hemodynamicand metabolicvariableswere made 10 min-
utes apartbefore ergonovinestimulation.The repro-
ducibilityof ourmeasurementsof coronarysinus flow was
estimatedby computingthedifference(mean ± standard
deviation)of thosemeasurementswhere the baseline heart
rate-systolicbloodpressureproduct varied by no more than
10%. The differencein coronarysinus flows was 0.1±
4.02ml/min ; thedifferencefor lactate was -0.4 ± 0.3
mg.
In the group as a whole , mean bloodpressureincreased
14% with the peak dose ofergonovine(p < 0.001).Heart
rate-systolicblood pressure productincreased25% (p <
0.001)and heart rateincreased11% (p < 0.05).Coronary
sinus flow,coronaryvascularesistance, lactatextraction,
arterial-coronarysinusoxygencontentdifferenceand myo-
cardialoxygenconsumptiondid notchange.However, a
subgroupof seven patients(GroupA) had an increase in
coronaryvascular esistance(Fig. I) . In theremainingpa-
tients(GroupB), coronarysinus flow andmyocardialox-
ygen consumptionincreasedby 38 and 40%,respectively
(p < 0.001 ), and there was aconcomitantslight increase
in heartrate-systolicblood pressureproduct of 16% (al-
though this did not reachstatisticalsignificance).In contrast,
in Group Apatients,despitea 36% (p< 0.02)increase in
heartrate-systolicblood pressureproduct ,coronarysinus
flowdecreasedby 14% (p< 0.02).Coronaryvasculare-
sistanceincreasedby 39% (range II to 75%, P< 0.00 I).
Therewere nodifferencesin tile baselineabsolutevalues
for bloodpressure,heartrate-bloodpressureproduct,coro-
nary sinus flow,percentlactate ,myocardialoxygencon-
umptionand arterial-coronarysinus oxygencontentdif-
ference for the twogroups.
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Table 2.Hemodynamic Data
Blood Pressure (mm Hg)
SBP x HR CYR
Heart Rate (mm Hg CSF (rum Hg/ml ACOO~ 'k Lacta te MVO~
C E (beats/min) x 10-') (01I/11In) per min ) (m l/l rter) Extraction (ml/nun )
Case SiD M SiD M C E C E C E C E C E C E C E
Group A
I 137175 (95) 142/83 ( 101) 69 63 9.3 8.9 40 .9 34 I 2.30 3.00 122 III 37 35 5.0 3 K
3 90/64 (73) 110174 (86) 60 60 5.4 6.6 67.6 55.9 1.08 1.54 99 100 47 47 6.7 5.6
4 135/55 (82) 137/72 (94) 75 114 10.1 15.6 466 48 I I 75 1.95 115 128 33 50 54 6. 1
5 147170 (95) 190/85 (120) 77 8 1 11.2 15.4 28.9 24.K 3.33 484 II I 20 3.2
9 120170 (89) 165/90 (1 15) 63 72 8.0 11.9 104 .0 87.2 0.K6 I 32 137 129 50 25 14.3 11.2
10 102/60 (74) 124/80 (95) 89 118 9. 1 14.6 437 32.0 1.69 2.96 113 123 50 3.9
14 140175 (~6 7) 150/85 (107) 58 72 8. 1 108 445 40.3 220 260 132 134 29 44 S9 54
Mean 86.3 103 70 83 8.7 12 0 53.7 46. 1 I K926 11K 121 36 40 66 6.0
SO 102 12.1 II 23.7 1.8 35 24.9 20.9 0.K3 I 2 13 12.911.2 10 2 3.6 27
P value:
Group A,
C vs E < 0.002 NS < 002 < 0.02 < 0.0 1 NS NS NS
Group B
2 93/50 (64) ro1/56 (68) 68 5 1 4. 7 6. 1 44.2 576 1.45 I 18 138 138 17 33 6 1 7 9
6 125/65 (82) 125170 (88) 102 96 11.7 12.0 46.3 593 1.76 149 121 148 32 44 5.6 K.K
7 175/85 (1 12) 180/87 ( 118) 84 96 14.6 16.2 374 44.3 301 2.66 154 159 5.8 7.1
8 165/60 (90) 225/85 ( 132) 110 III 18 2 25.0 464 762 1 94 I 73 94 89 IK 18 44 6K
II 164175 <105) 160/80 (107) 96 99 15.7 158 125.0 168.0 0.K40.64 126 125 21 49 157 209
12 115170 ( 102) 170170 (103) 87 96 14.4 16.3 355 49 .7 290 2.09 155 160 62 5.5 8.0
13 125/64 (84) 137/67 (90) 8 1 78 10 I 107 86.0 II K.9 0.98 0.70 109 10K 73 4 1 9.4 14.0
15 143179 (100) 152/82 (105) 63 69 9.0 10 5 73 8108.5 I 34 0.97 11K 123 3K 40 87 13 4
Mean 92.4 101 .4 84 91 12.3 14.1 61.8 K6.6 1.78 1 43127 131 33 4 1 7.7 10.9
SO 15.4 17.0 20 13.9 43 5.7 31.1 44.3O.KI .70 21 3 24.921 2 13 9 3 7 4.9
P value'
Group B,
C vs. E NS Ns NS < 0.001 < 0.001 NS NS < 0.00 1
C, Group A
vs. C, Group B NS NS NS NS NS NS NS NS
Group A + B
Mean 90 102 78 85 10.4 13.1 58 . 1 68 . 1 I 83 1 98 123 125 36 39 74 8.8
SO 13 16 17.2 19.7 3.9 4.7 27.739.9 0.79 1.10 18 21 16.3 10.1 3.5 46
p value:
C vs E < 0.001 < 0.05 < 0.00 1 NS NS NS NS NS
ACDO , = artenal-coronary " nus oxygen content difference.C = control.CSF = coronary\ lnU\ Row. CVR = coronaryvascular revistance. D= drastolu ,E =
ergonovine.M = mean;MVO, = myocardial oxygen consumption:NS = not significant:p = probabrhty: S= vyxtohc,SBP X HR = \Y\lOlIcblood pressuretuneshean
rate,SD = standard deviation.
Discussion
Hemodynamic responses to ergonovineadministra-
tion.Ergonovine maleate is an ergot alkaloid that has been
used for provoking coro nary artery spasm for the diagnosis
of variant angina. Ergot alkaloids, in general, produce vaso-
constriction by a direct alpha-adrenergic stimulation of
receptors in smooth muscle cells in arteriesand veins, re-
sulting in an increase in arterial and venous tone. Ergot
alkaloids may also produ ce alpha-blockingeffects in large
doses, andblunting of the baroreceptor response, mediated
by central nervous system mechan isms. Ergonovine ma-
leate, however , has less peripheralvasoconstrictioneffect
(17). In human subjects, the hemodynamic responses to the
usual dosesofergonovine maleate are an increase(5-8)or
no change in arter ial pressure, no change in heart rate(2,6-
8) and an increase in rate-pressure product (7,8) . In patients
without spasm, mild(1510 25%) diffuse narrowing of ep-
icardial coronary arteries is seen(5-8) with possibly a greater
effec t on smaller resistance arteries and arterioles (3-7).
This degree of narrowing has been thought to be insigni ficant
and myocardial oxygen extraction remains unchanged; no
electrocardiographic evidence of ischemia is observed. In
one study (7), an increase in myocardialoxygen extraction
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Table3. Response to Ergonovine
Percent Change
Chest ECG Thallium Lactate
Patient Pam Changes Scan HR BP HR x SBP CSF CVR Extraction ACOO~ MVO~
Group A
I + -8.7 +6.3 -43 -16.6 +30A -5 -91 -24
3 + 0.0 + 18.3 +22.2 -17.3 +43.0 -6 +0.9 -16
4 + 52.0 + 14.7 +54.5 +3.2 + IIA +52 +11.0 + 13
5 + 5.9 +26.3 +37.5 -14.0 +45.3
9 + 14.3 +29.0 +49.0 -16.0 +53.0 +50 -6.0 +1
10 + 33.0 +28.0 +61.0 -27.0 +75.0 +9.0 -22
14 + 24 10.3 +33.0 -94 + 18.0 48 1.0 -8A
Mean 19 17.2 36.1 -13.9 39A 7.8 t:2 -13.2
SO 9 20.9 22.2 9.2 21.7 42.6 0.1 14.1
Group B
2 17.6 6.2 29.8 +30.0 -19.0 +94 0.0 30
6 -59 8 I 2.6 23.0 -15.3 +38 22.0 57
7 +6.7 48 18.8 18A -4.2 3A 22
8 + 1.0 46.2 374 64.2 -10.8 0 -5.3 55
II + 3.0 2.0 1.0 34.0 -24.0 133 - 1.0 +33
12 + 10.3 I 5 13.2 40.0 -28.0 3.0 45
13 + -3.7 7.1 5.9 50.0 -29.6 -44 15.0 28
15 9.5 50 17.0 47.0 -28.0 32 4.0 54
Mean 10.1 48 15.7 38.3 -19.9 42 I 1.3 40A
SO 147 7.8 12.9 15.1 9.2 63.7 .3 13.9
P value
Group A vs. B NS NS P < 0.05 P< 0.001 < 0001 NS NS < 0.001
Group A + Group B
Mean 10.6 14.3 25.2 14.0 7.8 26.5 3A 17A
SO 16.1 12.8 20.2 29.6 34.3 55A 8.5 30.7
P value. C vs. E < 0 05 < 0.001 < 0.001 NS NS NS NS NS
BP = blood pressure:ECG = electrocardrographrc:otherabbrevration-,a m Table2
Figure1. Individual responses of percent change in
coronary sinus flow(6 CSF) and percent change in
coronary vascularresistance(6CVR) versuspercent
change in heart rale-systolic blood pressure (HR x
SBP) product 2 minutes after the administration of
a total dose of 0.35 mg of ergonovine intravenously.
Values m patients whose coronary vascular rests-
ranee increased (Group A) are plotted with solid
lines; patients whose coronary vascular resistance
decreased (Group B) are plotted withdas edlines.
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was reported . Leftventricularend-diastolicpressureand
volume (7,8)increasewithergonovine.
In patients withsevereobstructivecoronaryartery dis-
ease,ergonovinemay precipitateclassicanginaassociated
withischemicelectrocardiographicchanges,presumablyas
a result ofincreasesin thedeterminantsof myocardialox-
ygen demand.In patientswith variantangina, ergonovine
induces focalcoronaryarteryspasm (85 to 100%) (5,8,10)
and reliablyreproducestheclinicalsyndrome.
Coronaryhemodynamics in patients withvariantan-
gina versus atypical chest painafterergonovine.Few
studies (5,7 ,8 , I0) havem asuredcoronaryblood flowunder
conditionsof spontaneousor provocablecoronaryartery
spasm.The lackof an increasein myocardialblood flow
has beendemonstratedin patientswith variant angina due
tocoronaryarteryspasm.In previousstudies, a 30 to 50%
decreasein coronarysinus flow wasobservedin patients
withdocumentedvariantanginaafterergonovineadminis-
tration(5,8,10).Calculatedcoronaryvascularesistancein-
creasedmore than 40%(5,8), and in somepatientsmyo-
cardiallactateproduction(5 ,6) andincreasedoxygenex-
traction(5, 10)occurred.In contrast, in patientswithout
variantangina, but withatypicalchestpain , nosignificant
change(5,7)oradecrease(8) incoronaryvascularesistance
was observedand coronarysinus flowincreased(5,7 ,8) .
Therewas also noelectrocardiographicand metabolicevi-
dence of myocardialischemia(6) in thesepatientsafter
ergonovineprovocation. Thesefindingssuggestedthat the
determinationof changesin coronaryhemodynamicsafter
administrationfergonovinemay be helpful in thediagnosis
of variantanginadue to focalcoronary artery spasm and in
differentiatingthesepatientsfrom those who present with
atypicalchestpain (5).
The resultsofour presentstudy ,however,indicate that
thediagnosisofvariantanginadue tocoronaryartery spasm
cannot be made on the basisofchangesincoronaryvascular
resistanceor coronarysinus flow alone aftergonovine
stimulation.Our patientpopulationcontainedno patients
withsignificantcoronaryarterydisease. Noneofour patients
hadclinicalor electrocardiographicevidenceofvariant an-
gina .Furthermore,afterergonovinestimulation, nopatient
developedchangesin the electrocardiogramor in myo-
cardialperfusionand there was nochangein lactate ex-
traction orarterial-coronarysinus oxygendifference.Al-
though 73%of patientsdevelopedtheirtypical chest pain
syndrome, thecausedoesnotappearto becardiacasjudged
from thesemetabolic, scintigraphicand electrocardio-
graphicvariables.Othercausesfor chest pain that can be
provokedwith ergonovineadministrationsuch asesopha-
geal spasm (18) are alsop ssible.
The expected systemic hemodynamic effects of ergonov-
ine were seen. An increasein bloodpressureand heart rate-
bloodpressureproductoccurredin almostallpatients. Yet,
in 7 of 15patients, coronaryvascular esistanceincreased
and no clinical ,electrocardiographic, metabolicor scinti-
graphicevidencefor myocardialischemiacouldbedetected.
This suggeststhat inresponseto ergonovine, a transient
increase incoronary vascularresistanceand decrease in
coronaryblood flow,despiteincreasedmyocardialoxygen
demand, can occur in normal subjects without variant angina.
These findings indicate that a wide variability in response
to ergonovine occurs in patients with normal coronary ar-
teries and normal left ventricular function. The changesin
coronaryvascularesistance in normalsubjectsoverlapthe
rangeof increasesthat have beenreportedforpatientswith
spasm . We did not do simultaneouscoronaryangiography,
but inotherstudiesthe observationof hemodynamically
minorchangesin the large picardialarteriesimpliesthat
the increasedcoronaryvascular esistanceprobablyoccurs
at anarteriolarlevel , as suggestedpreviously, and no sig-
nificant metabolicchangeswere recordedto indicatethat
thesechangesin resistancewere physiologically important.
Methodologicconsiderations.Coronary vascularresis-
tance is a functionof blood pressureand coronary sinus
flow. The measured valueofcoronarysinus flow, intum,
is the sumofa componentdue tomeasurementerrorand a
componentdue tophysiologicalterations incoronaryhemo-
dynamics.The componentdue tomeasurementerroris not
insignificant. Unrecognized changes in catheter position may
contributeto this error. One way this can happen is by
includingor excludingbranchesof the coronary venous
drainageas thecathetermoveseithermore distall y or more
proximallytherebychangingthecalculatedcoronary sinus
flow. A second way is by refluxof blood from the right
atrium into thecoronarysinus when thecatheteris too
proximallylocated (14). Wethereforetook care toposition
ourcatheterin themidcoronarysinus to prevent thiserror.
In doing so, weundoubtedlymissed thecontributionofveins
thatenterthecoronarysinus near itsostium,explainingthe
low flows recorded in somecases.However, becausewe
interpretedour data in terms of relativechangesin flow.
we believe ourconclusionsshould be valid.
It also needs to be emphasized that coronary sinus flow
is an estimate oftotal left ventricular arterial flow . Regional
contributionscannotbe distinguished. Furthermore, actual
arterial flow is not measured ,althoughcoronarysinus flow
has been shown tocorrelatewell with total leftventricular
arterial flow in the dog (13). Finally,decreases incoronary
sinus flow rnay result fromincreasesin the leftventricular
end-diastolicpressure which have beenreportedwith er-
gonovine(7,8) in theabsenceof coronary artery spasm.
Although someofthedecreasesincoronarysinus flow were
relatively small , so that measurementerrormay have con-
tributed significantl y to theobservationofthedecrease,our
findings are still valid. Even if nosignificantchangein
coronarysinus flow had been observed(that is, thedecrease
in observedcoronarysinus flow was totall yattributedto
measurementerror) , theresponseof thisgrouptoergono-
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vine would still be striking in the light of the significant
increase in heart rate-systolic blood pressure product (36%,
p < 0.02).
Coronary vascular resistance data must be interpreted
cautiously when the aforementioned factors contributing to
the measurement error in coronary sinus flow are consid-
ered. The reproducibility of repeated measurements in our
laboratory, which has a large experience in coronary sinus
flowdeterminations,is similar(5,7,8)to that in other lab-
oratories employing this technique. Our data indicate that
substantial increases in coronary vascular resistance (mean
39%, range 11 to 75%) can be seen in a subgroup in whom
average coronary sinus flow decreased significantly.
Clinical implications. Our findings indicate a range in
the responsiveness of coronary hemodynamics to ergonov-
ine provocation. Most patients without variant angina show
an increase in the determinants of oxygen demand in re-
sponse to ergonovine and an expected increase in coronary
sinus flow and decrease in coronary vascular resistance.
However, there is a group of patients who have an unex-
pected response to the drug, resulting in an increase in
coronary vascular resistance with an inappropriately small
increase or decrease in coronary sinus flow. Therefore, coro-
nary sinus flow and coronary vascular resistance measure-
ments alone may not be diagnostic of variant angina. As-
sociated hemodynamic findings,electrocardiograms,thallium
scans and metabolic values must also be considered in the
diagnosis of variant angina.
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